Skip to main content
. 2021 Sep;9(18):1412. doi: 10.21037/atm-21-3020

Figure 2.

Figure 2

HBV DNA reduction rate compared to the baseline (R = HBV DNA at the end of the follow-up period/baseline HBV DNA ×100%). (A) Data of all patients; (B) data of patients treated with ETV; (C) data of patients treated with TDF; (D) data of patients treated with TAF; (E) data of patients treated with other antiviral drugs, such as LDV or LAM, in combination with ADV. HBV, hepatitis B virus; ETV, entecavir; TAF, tenofovir alafenamide fumarate; LDV, telbivudine; LAM, lamivudine; ADV, adefovir.